Interleukin-12 in anti-tumor immunity and immunotherapy

Cytokine and Growth Factor Reviews

Volumn 13, Issue 2, 2002, Pages 155-168

  Colombo, Mario P ^a   Trinchieri, Giorgio ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiogenesis; Immunotherapy; Interferon ; Interleukin 12; Tumor resistance

Indexed keywords

CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12; RECOMBINANT PROTEIN;

ANEMIA; ANGIOGENESIS; ANIMAL; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL MODEL; CANCER; CANCER ADJUVANT THERAPY; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CELL CULTURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOPATHOGENIC EFFECT; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG POTENCY; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTOPENIA; METABOLISM; METHODOLOGY; MOUSE; NAUSEA AND VOMITING; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NEUTROPENIA; NONHUMAN; PHYSIOLOGY; SHORT SURVEY; TH1 CELL; THROMBOCYTOPENIA; TUMOR CELL; TUMOR IMMUNITY; REVIEW;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TUMOR CELLS, CULTURED;

EID: 0036005890     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(01)00032-6     Document Type: Short Survey

References (89)

1. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
2. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells
3. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
4. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells
5. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells
6. Mouse interleukin-12 (IL-12) p40 homodimer: A potent IL-12 antagonist
7. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity
8. Biosynthesis and posttranslational regulation of human IL-12
9. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
10. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells
11. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes
12. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
13. Requirement for valpha14 NKT cells in IL-12-mediated rejection of tumors
14. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12
15. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent
16. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases
17. Different requirements for alpha-galactosylceramide and recombinant IL-12 antitumor activity in the treatment of C-26 colon carcinoma hepatic metastases
18. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells
19. CD4 T cells inhibit in vivo CD8-mediated immune response against a murine colon carcinoma transduced with IL-12 genes
20. Regulatory T cells in the control of immune pathology
21. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor
22. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk
23. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases
24. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha
25. Cytokines, tumour-cell death and immunogenicity: A question of choice
26. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12
27. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice
28. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells
29. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation
30. B7-1 and interleukin 12 synergistically induce effective antitumor immunity
31. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
32. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12
33. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major
34. IL-12 as an adjuvant for cell-mediated immunity
35. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
36. Interleukin-12 as an adjuvant for cancer immunotherapy
37. Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression
38. Immune suppression by recombinant interleukin (rIL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: Inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect
39. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis
40. Studies on the role of interleukin-12 in acute murine toxoplasmosis
41. Inhibition of angiogenesis in vivo by interleukin 12
42. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
43. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12
44. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12
45. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein
46. A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma
47. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
48. Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
49. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12
50. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-y1)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide]: Analysis of drug adducts by fluorescent antibodies vs. bound radioactivity
51. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations
52. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
53. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy
54. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP-10 and Mig
55. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells
56. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity
57. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells
58. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12
59. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk
60. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
61. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia
62. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
63. Tamoxifen for the prevention of breast cancer
64. IL-12 treatment of endogenously arising murine brain tumors
65. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene
66. Differential tumor surveillance by natural killer (NK) and NKT cells
67. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides
68. KRN7000, a novel immunomodulator, and its antitumor activities
69. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000
70. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
71. Toll meets bacterial CpG-DNA
72. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
73. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
74. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer
75. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: A gynecologic oncology group study
76. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
77. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer
78. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this adaptive response in mice
79. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma
80. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12
81. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses
82. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy
83. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study
84. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
85. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma
86. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12
87. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency
88. Inherited interleukin 12 deficiency in a child with Bacille Calmette-Guerin and Salmonella enteritidis disseminated infection
89. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo